AVTX Stock Overview
A clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Avalo Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.13 |
| 52 Week High | US$34.46 |
| 52 Week Low | US$3.95 |
| Beta | 1.03 |
| 11 Month Change | -29.85% |
| 3 Month Change | 1.30% |
| 1 Year Change | -52.04% |
| 33 Year Change | -99.83% |
| 5 Year Change | -99.91% |
| Change since IPO | -99.91% |
Recent News & Updates
Recent updates
Avalo to get ~15M upfront in license deal with Apollo Therapeutics for AVTX-007
Aug 01Avalo Therapeutics announces one-for-twelve reverse stock split
Jul 06Is Cerecor (NASDAQ:CERC) A Risky Investment?
Aug 10
Cerecor enters into $35M debt financing agreement with Horizon Technology Finance
Jun 07What Kind Of Investors Own Most Of Cerecor Inc. (NASDAQ:CERC)?
Mar 10Have Insiders Been Buying Cerecor Inc. (NASDAQ:CERC) Shares?
Jan 18Armistice Capital adds 2.5M Cerecor shares for $6.5M
Jan 13Cerecor slumps 12% on stock and pre-funded warrants offering
Jan 07Shareholder Returns
| AVTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -18.4% | 2.5% | 2.2% |
| 1Y | -52.0% | 16.1% | 31.6% |
Return vs Industry: AVTX underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: AVTX underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| AVTX volatility | |
|---|---|
| AVTX Average Weekly Movement | 14.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AVTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AVTX's weekly volatility has decreased from 54% to 15% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 19 | Garry Neil | www.avalotx.com |
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company’s drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases.
Avalo Therapeutics, Inc. Fundamentals Summary
| AVTX fundamental statistics | |
|---|---|
| Market cap | US$106.00m |
| Earnings (TTM) | -US$8.13m |
| Revenue (TTM) | US$820.00k |
129.3x
P/S Ratio-13.0x
P/E RatioIs AVTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVTX income statement (TTM) | |
|---|---|
| Revenue | US$820.00k |
| Cost of Revenue | US$10.16m |
| Gross Profit | -US$9.34m |
| Other Expenses | -US$1.21m |
| Earnings | -US$8.13m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.78 |
| Gross Margin | -1,139.27% |
| Net Profit Margin | -992.07% |
| Debt/Equity Ratio | 0% |
How did AVTX perform over the long term?
See historical performance and comparison